Central to the lawsuit is the claim that the company's "optimistic forecasts" about CagriSema's effectiveness ... asked questions about the Novo Nordisk case and our investigation, read more » ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15 ...

Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...

The case, filed in the U.S. District Court for ... committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who acquired Novo Nordisk securities ...